M
Masashi Mizokami
Researcher at Nagoya City University
Publications - 684
Citations - 37168
Masashi Mizokami is an academic researcher from Nagoya City University. The author has contributed to research in topics: Hepatitis B virus & Hepatitis C virus. The author has an hindex of 85, co-authored 650 publications receiving 34868 citations. Previous affiliations of Masashi Mizokami include National Institute of Advanced Industrial Science and Technology & University of Florida.
Papers
More filters
Journal Article
Interferon-alpha therapy exerts selective pressure on hepatitis C virus quasispecies equilibrium.
Masashi Mizokami,Tomoyoshi Ohno,Ken-ichi Ohba,Gary L. Davis,Kaoru Suzuki,Etsuro Orito,Joseph Lau +6 more
TL;DR: It is suggested thatIFN therapy exerts selective pressure on HCV quasispecies equilibrium, which drifted during IFN therapy but moved back in the direction of the original equilibrium during biochemical relapse.
Journal ArticleDOI
Prevalence of equine hepacivirus infection in Mongolia.
Tomoko Date,Masaya Sugiyama,Damdindorj Lkhagvasuren,Takaji Wakita,Tsendsuren Oyunsuren,Masashi Mizokami +5 more
TL;DR: Results indicate a relatively higher frequency of EHV infection in Mongolia than in Europe or North America, with virus strains divided into at least two subgenotypes.
Journal ArticleDOI
Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial.
Kentaro Matsuura,Yasuhito Tanaka,Atsunori Kusakabe,Shuhei Hige,Jun Inoue,Masashi Komatsu,Tomoyuki Kuramitsu,Katsuharu Hirano,Tomoyoshi Ohno,Izumi Hasegawa,Haruhiko Kobashi,Keisuke Hino,Yoichi Hiasa,Hideyuki Nomura,Fuminaka Sugauchi,Shunsuke Nojiri,Takashi Joh,Masashi Mizokami +17 more
TL;DR: There was no evidence on whether switching treatment to ETV‐ or LAM‐continuous treatment was better in patients treated with LAM for more than 3 years who maintained hepatitis B virus (HBV) DNA less than 2.6 log copies/mL.
Journal ArticleDOI
Frequent Detection of Hepatitis C Virus Subtype 3a (HCV-3a) Isolates in Thailand by PCR Using Subtype-Specific Primers
Chatchawann Apichartpiyakul,Hirofumi Miyajima,Hisaya Doi,Masashi Mizokami,Morio Homma,Hak Hotta +5 more
TL;DR: Serotype analysis of the HCV isolates using C 14‐1 and C14‐2 recombinant peptides revealed that HCV‐3a was likely to carry an antigenic determinant(s) different from those of the major types 1 and 2 (HCV‐2a and −2b).
Journal ArticleDOI
Incidence of anti-HTLV-1 antibody in liver disease
Hitoshi Nakano,Michio Sata,Kazuhiko Hino,Tomoki Aritaka,Naoto Maruyama,Teruko Hino,Hirohiko Abe,Kyuichi Tanikawa,Masashi Mizokami +8 more
TL;DR: The data suggest that the high incidence of anti-HTLV-1 in patients with liver disease was due to the transmission of HTLV- 1 by the same routes (maternal transmission and blood transfusion) and probably at the same time as the hepatitis viruses (HBV and hepatitis C virus).